Online Program Home
  My Program
CC = Baltimore Convention Center,    H = Hilton Baltimore
* = applied session       ! = JSM meeting theme

Activity Details

CE_03C Sat, 7/29/2017, 8:30 AM - 5:00 PM H-Holiday Ballroom 4
Bayesian Designs for Phase I-II Clinical Trials (ADDED FEE) — Professional Development Continuing Education Course
ASA , Biometrics Section , Section on Bayesian Statistical Science
This one-day short course will cover a variety of Bayesian sequentially adaptive phase I-II clinical trial designs that use both efficacy and toxicity to optimize dose, the dose pair of a two-agent combination, two doses given in sequence, or dose and schedule. The course will begin with an explanation of fundamental flaws with the conventional paradigm that separates phase I and phase II, followed by an overview of phase I-II designs. The remainder of the course will cover specific designs, with each illustrated by a practical application, including basic design structure, establishing numerical values of design parameters and prior parameters, and computer simulations to establish operating characteristics. Examples will include designs based on efficacy-toxicity probability trade-offs or elicited joint utilities of efficacy and toxicity, designs with binary, categorical, or time-to-event outcomes, methods for dealing with late onset outcomes, personalized (precision) dose-finding, optimizing molecularly targeted agents, two-agent combination trials, and methods for dealing with drop-outs.
Instructor(s): Peter Thall, M.D. Anderson Cancer Center, Ying Yuan, M.D. Anderson Cancer Center
Copyright © American Statistical Association